Taro Pharmaceutical Industries Ltd. TARO
Jun 21, 2024, 3:59 PM EDT
52-week range unavailable
- Market cap
- 1.62B
- Revenue (ttm)
- 629.18M
- Profit margin
- 8.56%
- Shares out
- 37.58M
- Forward P/E
- 9.79
- Volume
- 147.06K
- Open
- 42.97
- Previous close
- 42.98
- Day's range
- 42.94 – 42.98
- Beta
- 0.56
- Analysts
- Hold
- Price target
- 43.00 (+0.1%)
- Earnings date
- Jul 24, 2024
Key statistics
- Enterprise value
- 735.67M
- PEG ratio
- 0.00
- Price / sales
- 2.57
- Price / book
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.50%
- Free cash flow
- 21.04M
- Total cash
- 879.35M
- Total debt
- 0
- Return on equity
- 3.06%
- Short % of float
- 0.91%
- 50-day average
- 42.53
- 200-day average
- 40.34
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Jul 24, 2024
Expected Jul 24, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 24, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 20, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Jan 25, 2024 | Dec 1, 2023 | 0.30 | — | — | — |
| Oct 26, 2023 | Sep 1, 2023 | 0.18 | — | — | — |
| Jul 26, 2023 | Jun 1, 2023 | 0.31 | — | — | — |
| May 23, 2023 | Mar 1, 2023 | 0.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 24, 2023 | HC Wainwright & Co. | main | — | Buy |
| Aug 14, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jan 30, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jan 17, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 27, 2021 | HC Wainwright & Co. | main | — | Buy |
| Jun 1, 2021 | HC Wainwright & Co. | main | — | Buy |
About Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- Israel
- Website
- taro.com
News
Earnings Scheduled For January 25, 2024 
Earnings Scheduled For October 26, 2023 
Earnings Scheduled For July 26, 2023 
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Stocks That Hit 52-Week Lows On Wednesday
Earnings Scheduled For October 27, 2022 
Stocks That Hit 52-Week Lows On Monday - Earnings Scheduled For July 27, 2022
Stocks That Hit 52-Week Lows On Friday - Earnings Scheduled For January 27, 2022
Your note
Sign in to keep a note on TARO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FRANKLIN RESOURCES INC | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 31, 2010 | 0 |
| SUN PHARMACEUTICAL INDUSTRIES, LTD. | Affiliated Person | Purchase | Nov 3, 2010 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Krensavage Asset Management, LLC | 1.71% | 643,080 | 24.39M | Jun 29, 2023 |
| Renaissance Technologies, LLC | 1.58% | 594,900 | 22.56M | Jun 29, 2023 |
| Blackrock Inc. | 1.55% | 581,838 | 22.07M | Jun 29, 2023 |
| Dimensional Fund Advisors LP | 1.47% | 552,162 | 20.94M | Jun 29, 2023 |
| Brandes Investment Partners L.P. | 1.26% | 472,899 | 17.94M | Jun 29, 2023 |
| Eversept Partners, LP | 0.67% | 250,286 | 9.49M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco ETF Tr-Invesco Dynamic Pharmaceuticals ETF | 0.71% | 266,801 | 10.57M | Aug 30, 2023 |
| Columbia Fds Ser Tr I-Columbia Small Cap Value Fd I | 0.51% | 191,453 | 7.00M | Jul 30, 2023 |
| iShares Russell 2000 ETF | 0.49% | 184,497 | 7.31M | Aug 30, 2023 |
| Brandes International Small Cap Equity Fund | 0.22% | 83,250 | 3.16M | Jun 29, 2023 |
| DFA U.S. Core Equity 2 Portfolio | 0.22% | 83,253 | 3.04M | Jul 30, 2023 |
| Fidelity Small Cap Index Fund | 0.20% | 73,507 | 2.69M | Jul 30, 2023 |